Izalontamab brengitecan (iza-bren; BL-B01D1), a first-in-class bispecific antibody-drug conjugate, showed significantly better and more durable outcomes than chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who had already undergone multiple treatments. In the Phase 3 BL-B01D1-301 trial involving 386 patients who had received at least two prior therapies, including platinum-based chemotherapy and a […]

A major international clinical trial showed that adding the drug enzalutamide to standard hormone therapy can cut the risk of death by over 40% in men whose prostate cancer returns after initial surgery or radiation. This combination therapy was tested on over 1,000 men with high-risk recurrent prostate cancer—meaning their PSA levels (a marker for the disease) were rising

Researchers have found that triple-negative breast cancer (TNBC) depends heavily on lipids—fatty acids in the body—for its growth, linking obesity to more aggressive tumor development. In preclinical mouse models, excess lipids accelerated tumor growth, while reducing lipid levels slowed it significantly. Lipids appear to act as “building blocks” that fuel rapid cancer cell proliferation. These

The phase 3 POTOMAC trial found that combining durvalumab (Imfinzi) with BCG induction and maintenance therapy significantly improved outcomes for patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). Patients receiving durvalumab with BCG induction and maintenance experienced a 32% reduction in the risk of disease-free survival (DFS) events (HR 0.68; P=0.0154), with benefits observed early and sustained throughout follow-up.

A phase 2 study presented at the 2025 ESMO Congress compared lenvatinib plus everolimus with cabozantinib in patients with metastatic clear cell renal cell carcinoma whose disease progressed after PD-1 immunotherapy. The study included 86 patients, most of whom had previously received nivolumab or ipilimumab. The combination of lenvatinib and everolimus significantly improved progression-free survival,